Navdeep is a Michael J. Fox Foundation Postdoctoral Fellow at Elan Pharmaceuticals. She previously completed a postdoctoral fellowship at Stanford University studying the role of the endogenous Src tyrosine kinase inhibitor RACK1 as a potential therapeutical for colorectal cancer. Navdeep received her genetics PhD and BS from the University of California, Davis, where her studies focused on the role of cyclin E overexpression in the etiology and progression of breast cancer, particularly in its ability to cause resistance to the chemotherapeutic drug tamoxifen.
Her current research focuses on elucidating regulatory and catalytic mechanisms for parkin E3 ubiquitin ligase activity, and its role in Parkinson's disease (PD). Although the etiology of PD is known, the molecular mechanism of PD pathogenesis and the discovery of a mechanism to reverse neurodegeneration remain to be elucidated. Her goals as a postdoctoral fellow at Elan are to discover how parkin deregulation promotes PD and how it can be used as a target for treatment in patients with PD.
Her current research focuses on elucidating regulatory and catalytic mechanisms for parkin E3 ubiquitin ligase activity, and its role in Parkinson's disease (PD). Although the etiology of PD is known, the molecular mechanism of PD pathogenesis and the discovery of a mechanism to reverse neurodegeneration remain to be elucidated. Her goals as a postdoctoral fellow at Elan are to discover how parkin deregulation promotes PD and how it can be used as a target for treatment in patients with PD.